سعر اسبوسيد 75مجم 30 قرص 2024

Aspocid (acetylsalicylic acid 75 mg) tablets from CID, a low-dose antiplatelet; pack of 30 tablets (3 strips).

• Secondary prevention of myocardial infarctionPopulation: Adultselectronic medicines compendium (eMC)
• Prevention of cardiovascular morbidity in patients with stable angina pectorisPopulation: Adultselectronic medicines compendium (eMC)
• History of unstable angina pectoris, except during the acute phasePopulation: Adultselectronic medicines compendium (eMC)

• Common: dyspepsia, nausea, vomiting, diarrhoea; increased bleeding tendency.International label, equivalent formulation · electronic medicines compendium (eMC)
• Uncommon to rare: hypersensitivity reactions including angioedema and anaphylaxis, urticaria, rhinitis, dyspnoea, severe gastrointestinal haemorrhage, intracranial haemorrhage, haemorrhagic vasculitis. Not known: gastric or duodenal ulcers and perforation, bronchospasm, tinnitus and reduced hearing, hyperuricaemia, impaired renal function, hepatic enzyme increase, severe skin reactions.International label, equivalent formulation · electronic medicines compendium (eMC)

• Hypersensitivity (e.g. asthma, rhinitis, angioedema, urticaria) to salicylates or NSAIDs, or a history of asthma induced by them.International label, equivalent formulation · electronic medicines compendium (eMC)
• Acute gastrointestinal ulcers; history of NSAID-related gastrointestinal bleeding or perforation; active or recurrent peptic ulcer/haemorrhage or other bleeding such as cerebrovascular haemorrhage.International label, equivalent formulation · electronic medicines compendium (eMC)
• Haemorrhagic diathesis and coagulation disorders such as haemophilia and thrombocytopenia; severe hepatic or renal impairment; severe cardiac insufficiency.International label, equivalent formulation · electronic medicines compendium (eMC)

• Not suitable for use as an anti-inflammatory, analgesic or antipyretic at this dose.International label, equivalent formulation · electronic medicines compendium (eMC)
• Increased risk of haemorrhage and prolonged bleeding time, particularly during or after surgery (including minor procedures such as tooth extraction); temporary discontinuation may be necessary. Report any unusual bleeding; withdraw if gastrointestinal bleeding or ulceration occurs.International label, equivalent formulation · electronic medicines compendium (eMC)
• May promote bronchospasm, asthma attacks or other hypersensitivity reactions (risk factors: asthma, hay fever, nasal polyps, chronic respiratory disease). Rare Kounis syndrome (hypersensitivity-related acute myocardial ischaemia) has been reported.International label, equivalent formulation · electronic medicines compendium (eMC)

• Methotrexate (>15 mg/week)Contraindicated: aspirin decreases renal clearance of methotrexate and increases its haematological toxicity.electronic medicines compendium (eMC)
• Uricosuric agents (probenecid, sulfinpyrazone)Not recommended: salicylates reverse the uricosuric effect.electronic medicines compendium (eMC)
• Anticoagulants and thrombolyticsIncreased bleeding risk; monitor for bleeding. Do not start aspirin within 24 hours after alteplase in acute stroke.electronic medicines compendium (eMC)

• Low quantities of salicylates pass into breast milk; short-term use of the recommended dose does not require suspending breastfeeding.International label, equivalent formulation · electronic medicines compendium (eMC)

• Acetylsalicylic acid (aspirin): Irreversibly inhibits cyclo-oxygenase enzymes by acetylation, reducing prostaglandin synthesis (analgesic, antipyretic and anti-inflammatory effects) and, in platelets, blocking thromboxane A2 synthesis for the lifespan of the platelet (7-10 days), which inhibits platelet aggregation.